Sex differences in outcomes of methadone maintenance treatment for opioid addiction: A systematic review protocol

Systematic Reviews

Volumn 3, Issue 1, 2014, Pages

  Bawor, Monica ^a,b   Dennis, Brittany B ^a,b   Anglin, Rebecca ^a   Steiner, Meir ^a,c   Thabane, Lehana ^a,d   Samaan, Zainab ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

Methadone maintenance treatment; Opioid addiction dependence; Protocol; Sex differences; Systematic review

Indexed keywords

METHADONE; OPIATE; NARCOTIC AGENT;

ABSTINENCE; ARTICLE; CRIMINAL BEHAVIOR; DRUG ABUSE; DRUG SEEKING BEHAVIOR; EMPLOYMENT; HEALTH STATUS; HUMAN; META ANALYSIS; MORTALITY; OPIATE ADDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SEX DIFFERENCE; SEXUAL BEHAVIOR; SOCIAL SUPPORT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; METHODOLOGY; OPIATE SUBSTITUTION TREATMENT; REVIEW;

FEMALE; HUMANS; MALE; METHADONE; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84907276029     PISSN: None     EISSN: 20464053     Source Type: Journal    
DOI: 10.1186/2046-4053-3-45     Document Type: Article

References (51)

1. Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med 2010, 363:1981-1985.
2. CDC: Multiple cause of death data. In National Vital Statistics System. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
3. Fischer B, Keates A, Buhringer G, Reimer J, Rehm J: Non-medical use of prescription opioids and prescription opioid-related harms: why so markedly higher in North America compared to the rest of the world? Addiction 2013, 109:177.
4. Firestone Cruz M, Fischer B, Patra J, Kalousek K, Newton-Taylor B, Rehm J, Tyndall M: Prevalence and associated factors of hepatitis C infection (HCV) in a multi-site Canadian population of illicit opioid and other drug users (OPICAN). Can J Public Health 2007, 98:130-133.
5. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE: Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 1997, 54:71-80.
6. Hall W, Bell J, Carless J: Crime and drug use among applicants for methadone maintenance. Drug Alcohol Depend 1993, 31:123-129.
7. Mattick RP, Breen C, Kimber J, Davoli M: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009, 3:CD002209.
8. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. JAMA 1998, 280:1936-1943.
9. Fischer B: Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada. J Public Health Policy 2000, 21:187-210.
10. Fischer B, Cruz MF, Rehm J: Illicit opioid use and its key characteristics: a select overview and evidence from a Canadian multisite cohort of illicit opioid users (OPICAN). Can J Psychiatry 2006, 51:624-634.
11. Mental Health and Addiction Information: Methadone. Toronto, ON: CAMH; 2010 http://www.camh.ca/en/hospital/health_information/a_z_mental_ health_and_addiction_information/methadone/Pages/methadone.aspx.
12. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S: Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 2008, 12:109-124.
13. Fischer B, Medved W, Gliksman L, Rehm J: Illicit opiate users in Toronto: a profile of current users. Addict Res 1999, 7:377-415.
14. Fischer B, Rehm J, Patra J, Cruz MF: Changes in illicit opioid use across Canada. CMAJ 2006, 175:1385.
15. Substance Abuse and Mental Health Services Administration: Summary of findings from the 2000 National Household Survey on Drug Abuse. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2001.
16. Back SE, Lawson KM, Singleton LM, Brady KT: Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav 2011, 36:829-834.
17. Chatham LR, Hiller ML, Rowan-Szal GA, Joe GW, Simpson DD: Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse 1999, 34:1137-1165.
18. Back SE, Payne RL, Simpson AN, Brady KT: Gender and prescription opioids: findings from the National Survey on Drug Use and Health. Addict Behav 2010, 35:1001-1007.
19. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W: Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011, 37:313-323.
20. Maremmani I, Stefania C, Pacini M, Maremmani AG, Carlini M, Golia F, Deltito J, Dell'Osso L: Differential substance abuse patterns distribute according to gender in heroin addicts. J Psychoactive Drugs 2010, 42:89-95.
21. Chen CK, Shu LW, Liang PL, Hung TM, Lin SK: Drug use patterns and gender differences among heroin addicts hospitalized for detoxification. Changgeng Yi Xue Za Zhi 1998, 21:172-178.
22. Lin HC, Chang YP, Wang PW, Wu HC, Yen CN, Yeh YC, Chung KS, Chang HC, Yen CF: Gender differences in heroin users receiving methadone maintenance therapy in Taiwan. J Addict Dis 2013, 32:140-149.
23. Acharyya S, Zhang H: Assessing sex differences on treatment effectiveness from the drug abuse treatment outcome study (DATOS). Am J Drug Alcohol Abuse 2003, 29:415-444.
24. Greenfield SF, Brooks AJ, Gordon SM, Green CA, Kropp F, McHugh RK, Lincoln M, Hien D, Miele GM: Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend 2007, 86:21.
25. Goldbarg RN, Brown EJ: Gender, personal networks, and drug use among rural African Americans. Int Q Community Health Educ 2009, 30:41-54.
26. Substance Abuse and Mental Health Services Administration Oo, National ASTEDST, Admissions to Substance Abuse Treatment Service DSS-, DHHS Publication No. (SMA) 04-3965: Treatment Episode Data Set (TEDS): 1992-2002. In National Admissions to Substance Abuse Treatment Service, DASIS Series: S-23 vol. Rockville, MD: DHHS Publication No. (SMA) 04-3965; 2004.
27. Haney M: Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007, 32:1391-1403.
28. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS, Friedland GH: Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health 1995, 85:83-88.
29. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE: Gender and non-medical use of prescription opioids: results from a national US survey. Addiction 2008, 103:258-268.
30. Crettol S, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Deglon JJ, Preisig M, Eap CB: Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1722-1727.
31. Tsao JC, Stein JA, Dobalian A: Sex differences in pain and misuse of prescription analgesics among persons with HIV. Pain Med 2010, 11:815-824.
32. Kang SY, Deren S, Colon H: Gender comparisons of factors associated with drug treatment utilization among Puerto Rican drug users. Am J Drug Alcohol Abuse 2009, 35:73-79.
33. Sordo L, Chahua M, Bravo MJ, Barrio G, Brugal MT, Domingo-Salvany A, Molist G, De la Fuente L: Depression among regular heroin users: the influence of gender. Addict Behav 2012, 37:148-152.
34. Okoli CTC, Khara M, Torchalla I, Ensom MHH, Oliffe JL, BottorffJL, Stanley PJ: Sex differences in smoking cessation outcomes of a tailored program for individuals with substance use disorders and mental illness. Addict Behav 2011, 36:523-526.
35. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, Kurz M: Gender differences in health-related quality of life on admission to a maintenance treatment program. Eur Addict Res 2005, 11:69-75.
36. Jones HE, Fitzgerald H, Johnson RE: Males and females differ in response to opioid agonist medications. Am J Addict 2005, 14:223-233.
37. Savage LJ, Simpson DD: Posttreatment outcomes of sex and ethnic groups treated in methadone maintenance during 1969-1972. J Psychedelic Drugs 1980, 12:55-64.
38. Peles E, Adelson M: Gender differences and pregnant women in a methadone maintenance treatment (MMT) clinic. J Addict Dis 2006, 25:39-45.
39. Marsh KL, Simpson DD: Sex differences in opioid addiction careers. Am J Drug Alcohol Abuse 1986, 12:309-329.
40. Grella CE, Lovinger K: Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence. Addict Behav 2012, 37:306-312.
41. Mulvaney FD, Brown LS Jr, Alterman AI, Sage RE, Cnaan A, Cacciola J, Rutherford M: Methadone-maintenance outcomes for Hispanic and African-American men and women. Drug Alcohol Depend 1999, 54:11-18.
42. Magura S, Kang S-Y, Rosenblum A, Handelsman L, Foote J: Gender differences in psychiatric comorbidity among cocaine-using opiate addicts. J Addict Dis 1998, 17:49-61.
43. Rutherford MJ, Alterman AI, Cacciola JS, Snider EC: Gender differences in diagnosing antisocial personality disorder in methadone patients. Am J Psychiatry 1995, 152:1309-1316.
44. Steer RA, Kotzker E: Affective changes in male and female methadone patients. Drug Alcohol Depend 1980, 5:115-122.
45. Jimenez-Trevino L, Saiz PA, Garcia-Portilla MP, Diaz-Mesa EM, Sanchez-Lasheras F, Buron P, Casares MJ, Marina P, Gutierrez E, Bobes J: A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences. Addict Behav 2011, 36:1184-1190.
46. Camacho LM, Bartholomew NG, Joe GW, Cloud MA, Simpson DD: Gender, cocaine and during-treatment HIV risk reduction among injection opioid users in methadone maintenance. Drug Alcohol Depend 1996, 41:1-7.
47. Wells EA, Calsyn DA, Clark LL, Jackson TR, Saxon AJ: Retention in methadone maintenance is associated with reductions in different HIV risk behaviors for women and men. Am J Drug Alcohol Abuse 1996, 22:509-521.
48. Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa statistic. Fam Med 2005, 37:360-363.
49. Wells G, Shea B, O'connell D, Peterson J, Welch V, Losos M, Tugwell P: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa, ON: Ottawa Health Research Institute; 1999.
50. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA: The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
51. Moher D, Liberati A, TetzlaffJ, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6:e1000097.